REP 2055

Drug Profile

REP 2055

Alternative Names: REP 9AC

Latest Information Update: 18 Nov 2015

Price : $50

At a glance

  • Originator REPLICor; University of Adelaide
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Hepatitis B

Most Recent Events

  • 18 Nov 2015 Interim pharmacodynamics data from a preclinical study in Hepatitis B infection released by REPLICor
  • 07 Oct 2014 REPLICor completes a phase I/II trial in Hepatitis B infection
  • 07 Oct 2014 Efficacy and adverse events data from a phase I/II trial in Hepatitis B infection released by REPLICor ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top